Nykode Therapeutics ASA (5VB)

Overview

Nykode Therapeutics AS is a forward-thinking biopharmaceutical firm predominantly engaged in the discovery and development of innovative immunotherapies. Positioned as a clinical-stage entity, the company harnesses its expertise to pioneer vaccine solutions aimed at combating cancer and infectious diseases. Founded in the year 2006 and anchored in Oslo, Norway, Nykode Therapeutics AS demonstrates a commitment to advancing healthcare through strategic partnerships and a robust R&D foundation. The company benefits from collaboration agreements with industry giants such as Roche, Genentech, MSD, and Nektar Therapeutics, in addition to alliances for T cell vaccine development with Adaptive Biotechnologies and a research pact with Regeneron. These collaborations emphasize the company's proactive approach in harnessing external expertise and technologies to bolster its product pipeline and accelerate development timelines.

Products and Services

VB10.NEO

This innovative cancer neoantigen vaccine lies at the heart of Nykode Therapeutics' portfolio. VB10.NEO is currently navigating through a phase I/IIa clinical trial, showcasing its potential as a groundbreaking immunotherapy for a variety of cancers, including melanoma, lung, bladder, renal, head, and neck cancer. By targeting neoantigens, which are novel antigens presented by cancer cells, VB10.NEO is designed to provoke a robust and specific immune response against the cancer, distinguishing it as a personalized treatment approach.

VB10.16

VB10.16 enters the therapeutic arena as a promising vaccine aimed at addressing human papilloma virus (HPV) 16 induced malignancies, with a particular focus on cervical cancer. Currently in a phase II clinical trial, VB10.16 represents a strategic push towards therapeutic vaccines, aiming to create a meaningful impact on the prevention and treatment of HPV-related cancers by stimulating an immune response against the HPV16 virus, the primary cause of cervical and other anogenital cancers.

VB10.COV2

In response to the global COVID-19 pandemic, Nykode Therapeutics has expanded its vaccine development efforts to include VB10.COV2, a candidate vaccine against COVID-19. This project aims to address the ongoing challenges posed by new SARS-CoV-2 variants through a potentially adaptable and responsive vaccine design. VB10.COV2 underscores the company's flexibility and dedication to contributing to global health security by aiming to provide a robust defense against the evolving COVID-19 virus.